Related Experiment Video
Updated: Apr 21, 2026

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion
Published on: March 31, 2022
Controversies in ASSAY and drug development technologies: a focus on assessing irreproducibility
J Fraser Glickman1, Thomas Lundbäck, Andrew D Napper
11 The Rockefeller University , New York, New York.
Abstract:
Has the impact of irreproducibility on the discovery and development of drugs, as with global warming, metaphorically speaking, crept up on us as we slept? Or is the problem more an issue of heightened awareness? We currently find ourselves in a time when the impact of irreproducibility can easily be amplified by the combinatorial effect of our increasing reliance on advanced technologies and unrealistic expectations of how scientific truths unfold. How and why we got here is a topic that has been written on extensively (1-3) and is probably as complex as any other problem, given the dependence of science today on so many external forces. Through a series of questions, we asked members of our editorial board their opinions on scientific irreproducibility. They chose to answer the same questions from different levels, indicating the depth of the problem and perhaps where they each believe change for the better needs to begin. My thanks to the participants.
More Related Videos
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
In Vitro Drug Release Testing: Overview, Development and Validation
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Clinically Relevant Drug Product Specifications: Methods of Establishment
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

